Immunodominance hierarchies and gender bias in direct T(CD8)-cell alloreactivity

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Nicole A MifsudJames McCluskey


Allogeneic solid organ transplantation often occurs across multiple donor-recipient HLA mismatches with consequent risk of allograft rejection. However, there is growing evidence that not all HLA mismatches are equivalent in their stimulation of allogeneic T cells making it important to determine which of these might be more significant as predictors of allograft rejection. To this end, we used defined antigen-presenting cell (APC) transfectants expressing single MHC-I allotypes as target cells that could discriminate the relative contribution of individual mismatched MHC-I allotypes to direct T-cell alloreactivity. We demonstrate remarkably reproducible patterns of immunodominance in reactivity across mismatched MHC-I allotypes. These patterns are HLA context-dependent, partly reflecting alloantigenic competition in responder cell responses. In strong alloresponses, we also observed an increased percentage of alloreactive T(CD8) cells in female responders, regardless of the stimulator gender, highlighting HLA-independent factors in the potency of the alloresponse. This approach provides a potential measure of specific alloreactive T cells that could be used in clinical practice for selection of donors, assessment of posttransp...Continue Reading


Apr 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·A BrooksJ McCluskey
May 1, 1991·Transplantation·B S Breur-VriesendorpP Ivanyi
Jan 1, 1990·Immunologic Research·R Lechler, G Lombardi
Dec 27, 1990·The New England Journal of Medicine·K FleischhauerS Y Yang
Feb 26, 1974·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·J E Castro
Jan 1, 1995·European Journal of Immunology·A HillA McMichael
Feb 15, 1995·Circulation·M E WechslerM L Barr
Jan 1, 1994·Journal of Clinical Laboratory Analysis·J SteinmannW Müller-Ruchholtz
Apr 1, 1996·Clinical and Experimental Immunology·M MestreJ M Grinyo
Nov 27, 1996·International Journal of Cancer. Journal International Du Cancer·K FleischhauerC Traversari
Dec 27, 1996·Transplantation·B K BrooksG B Klintmalm
Sep 18, 1997·The Journal of Experimental Medicine·A LalvaniA J McMichael
Feb 10, 1998·The Annals of Thoracic Surgery·T W PrendergastV Jeevanandam
Jan 11, 2000·Nucleic Acids Research·J RobinsonS G Marsh
Apr 4, 2001·The Journal of Clinical Investigation·J S Bromberg, B Murphy
Jun 6, 2002·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·H-A Elsner, R Blasczyk

❮ Previous
Next ❯


Oct 8, 2009·Circulation. Heart Failure·Jennifer C Matthews, Keith D Aaronson
May 29, 2014·Journal of Immunology Research·Kirsten GeneugelijkEric Spierings
Aug 11, 2016·Immunology and Cell Biology·Thi Ho NguyenKatherine Kedzierska
Mar 3, 2010·Immunology and Cell Biology·Thi H O NguyenNicole A Mifsud
Apr 30, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Thi H O NguyenNicole A Mifsud
Nov 10, 2018·Nature Communications·Patricia T IllingAnthony W Purcell
Aug 21, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Louise C RowntreeNicole A Mifsud
Dec 14, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·C SmithR Khanna
Dec 27, 2019·Computational Biology and Chemistry·Asuman BunsuzPemra Ozbek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.